Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Currently amended) A compound of formula (I):



(I)

wherein:

R^1 represents phenyl which may be optionally substituted by one or more substituents which may be the same or different and which are selected from the group consisting of: halogen; trifluoromethyl; -C_{1-6}alkyl optionally substituted by $COOR^{15}$; -C_{1-6}alkoxy optionally substituted by $COOR^{15}$; hydroxy; oxo; cyano; -C_{1-6}alkyl-cyano; C_{1-6}alkenyl optionally substituted by $COOR^{15}$; C_{3-7}cycloalkyl; C_{1-6}alkylsulfonyl; C_{1-6}alkenoxy; C_{1-6}alkylthio; $NR^{15}R^{16}$; -C_{1-6}alkyl-aryl; aryl; -CO-aryl optionally substituted by halogen; -CO-heteroaryl; -CO-heterocyclyl; $-COOR^{15}$; $-COR^{15}$; $-CONR^{15}R^{16}$ optionally substituted by C_{1-6}alkyl, halogen or -C_{1-6}alkylC_{1-6}alkoxy; and -C_{1-6}alkyl-CO-aryl groups; and in which

R^{15} and R^{16} independently represent hydrogen, C_{1-6}alkyl or C_{3-8}cycloalkyl or together may be fused to form a 5- to 7-membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom and optionally substituted by a halogen, C_{1-6}alkyl or C_{1-6}alkylC_{1-6}alkoxy group;

Z represents CO;

r is 0;

p is 1;

m is 0;

R^3 represents group of formula (i):



(i)

wherein

f is 0;

g is 2;

h is 1;

k is 0; and

R^{13} represents C_{1-6}alkyl or C_{3-8}cycloalkyl;

or a pharmaceutically acceptable salt thereof.

~~R^1 represents hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-8} cycloalkyl, C_{1-6} alkyl C_{3-8} cycloalkyl, aryl, heterocyclyl, heteroaryl, C_{1-6} alkyl-aryl, C_{1-6} alkyl-heteroaryl, C_{1-6} alkyl-heterocyclyl, -aryl-aryl, -aryl-heteroaryl, -aryl-heterocyclyl, heteroaryl-aryl, -heteroaryl-heteroaryl, -heteroaryl-heterocyclyl, -heterocyclyl-aryl, -heterocyclyl-heteroaryl, -heterocyclyl-heterocyclyl,~~

~~wherein R^1 may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, $COOR^{15}$, cyano, C_{1-6} alkyl-cyano, nitro, oxo, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C_{1-6} alkyl (optionally substituted by a $COOR^{15}$ group), C_{2-6} alkenyl (optionally substituted by a $COOR^{15}$ group), C_{2-6} alkynyl (optionally substituted by a $COOR^{15}$ group), C_{1-6} alkoxy (optionally substituted by a $COOR^{15}$ group), pentafluoroethyl, C_{1-6} alkoxy, C_{2-6} alkenoxy, aryl, arylC_{1-6} alkyl, -CO-aryl (optionally substituted by a halogen atom), -CO-heteroaryl, C_{1-6} alkyl-CO-aryl, arylC_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxyC_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkylC_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonylC_{1-6} alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC_{1-6} alkyl, aryloxy, C_{1-6} alkylsulfonamido, C_{1-6} alkylamido, C_{1-6} alkylsulfonamidoC_{1-6} alkyl, C_{1-6} alkylamidoC_{1-6} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC_{1-6} alkyl, arylcarboxamidoC_{1-6} alkyl, aroyl, aroylC_{1-6} alkyl, arylC_{1-6} alkanoyl, or a group $-COR^{15}$, $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-NR^{15}SO_2R^{16}$ or $-SO_2NR^{15}R^{16}$, wherein R^{15} and R^{16} independently represent hydrogen, C_{1-6} alkyl or C_{3-8} cycloalkyl or together may be fused to form a 5- to 7- membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom and optionally substituted by a halogen, C_{1-6} alkyl or $-C_{1-6}$ alkylC_{1-6} alkoxy group;~~

~~Z represents a bond, CO, -CON(R^{10})- or SO_2, such that when R^4 represents hydrogen, Z represents $CONR^{10}$;~~

~~p is 1 or 2;~~

~~m, n and r independently represent 0, 1 or 2;~~

~~R^2 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl, such that when n represents 2, two R^2 groups may instead be linked to form a phenyl ring;~~

~~R^4 represents C_{1-6} alkyl, such that when r represents 2, two R^4 groups may instead be linked to form a CH_2, $(CH_2)_2$ or $(CH_2)_3$ group;~~

~~R^{10} represents hydrogen or C_{1-6} alkyl, or R^{10}, together with R^1 forms a heterocyclic group;~~

~~R^3 represents $-(CH_2)_q-NR^{11}R^{12}$ or a group of formula (i):~~



~~wherein q is 2, 3 or 4;~~

~~R^{11} and R^{12} independently represent C_{1-6} alkyl or C_{3-8} cycloalkyl or together with the nitrogen atom to which they are attached represent an N-linked nitrogen containing heterocyclyl group optionally substituted by one or more R^{17} groups;~~

~~R^{13} represents hydrogen, C_{1-6} alkyl, $-C_{1-6}$ alkyl-C_{1-6} alkoxy, C_{3-8} cycloalkyl, $-C_{1-6}$ alkyl-C_{3-8} cycloalkyl, $-C_{1-6}$ alkyl-aryl or heterocyclyl;~~

~~R^{14} and R^{17} independently represent halogen, C_{1-6} alkyl, haloalkyl, OH, diC_{1-6} alkylamino, C_{1-6} alkoxy or heterocyclyl;~~

~~f and k independently represent 0, 1 or 2;~~

~~g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0;~~

~~with the proviso that when m represents 1, n and r both represent 0 and R^3 represents $-(CH_2)_3$-N-piperidine or $-(CH_2)_3-N(ethyl)_2$, R^1-Z represents a group other than methyl, -CO-O-$C(CH_3)_3$ or benzyl;~~

~~and with the proviso that when m, n and r all represent 0, p represents 1, R^3 represents $-(CH_2)_3$-N-pyrrolidine or $-(CH_2)_3$-N-piperidine, R^1 represents benzyl, Z represents a group other than a bond;~~

~~and with the proviso that when m, n and r all represent 0, p represents 1, R^3 represents $-(CH_2)_3$-N-piperidine, R^1 represents isopropyl, Z represents a group other than a bond;~~

~~and with the proviso that when m represents 1, n and r both represent 0, p represents 1, R^3 represents $-(CH_2)_3$-N-piperidine, R^1 represents methyl, isopropyl, aryl or benzyl, Z represents a group other than a bond;~~
~~and with the proviso that when m and n both represent 0, R^3 represents $-(CH_2)_3$-$N(ethyl)_2$, p represents 1, r represents 2 and R^1 and R^4 both represent methyl, Z represents a group other than a bond;~~
~~or a pharmaceutically acceptable salt thereof.~~

2-11. (Cancelled)

Add the following new claims:

12. (New) A compound according to claim 1 wherein R^1 is phenyl which may be optionally substituted by 1, 2 or 3 substituents which may be the same or different and which are selected from the group consisting of: chlorine, fluorine, bromine; trifluoromethyl; methyl, ethyl, isopropyl, propyl, t-butyl (optionally substituted by COOH, COOMe or COOEt); methoxy, butoxy, $-OCH(Me)_2$, $-OC(Me)_3$ (optionally substituted by COOH or COOMe); hydroxy; oxo; cyano; $-CH_2$-CN; ethenyl (optionally substituted by COOMe); cyclopentyl; $-SO_2Me$; $-OCH_2CH=CH_2$; –S-ethyl; $N(Me)_2$; benzyl; phenyl; –CO-phenyl (optionally substituted by chlorine); –CO-azetidinyl; –CO-tetrahydropyranyl; COOH, COOMe, COOt-butyl; –CO-methyl, -CO-ethyl, -CO-isopropyl, -CO-cyclopropyl, -CO-cyclobutyl, -CO-cyclopentyl, -CO-cyclohexyl; $-CONH_2$, -CO-pyrrolidinyl, -CO-morpholinyl, -CO-piperazinyl, -CO-piperidinyl, -CO-thiomorpholinyl (optionally substituted by methyl, fluorine and $-CH_2OMe$); or $-CH_2$COphenyl groups;
or a pharmaceutically acceptable salt thereof.

13. (New) A compound according to claim 1 wherein R^1 is phenyl substituted by C_{1-6}alkylsulfonyl.

14. (New) A compound according to claim 1 wherein R^1 is phenyl substituted by SO_2Me.

15. (New) A compound according to claim 1 wherein R^1 is phenyl substituted by SO_2Me at the para position.

16. (New) A compound according to claim 1 wherein -O-R^3 is present at the para position of the phenyl group with respect to the rest of the compound.

17. (New) A compound according to claim 1 wherein R^{13} represents isopropyl, cyclopropyl or cyclobutyl.

18. (New) A compound according to claim 13, wherein R^{13} represents isopropyl, cyclopropyl or cyclobutyl.

19. (New) A compound according to claim 14, wherein R^{13} represents isopropyl, cyclopropyl or cyclobutyl.

20. (New) A compound which is 1-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-4-{[4-(methylsulfonyl)phenyl]carbonyl}piperazine or a pharmaceutically acceptable salt thereof.

21. (New) A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

22. (New) A method of treatment of diseases of the upper respiratory tract which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claims 1 or a pharmaceutically acceptable salt thereof.

23. (New) A method of treatment according to claim 21 in which the disease is allergic rhinitis.

24. (New) A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 18 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

25. (New) A method of treatment of diseases of the upper respiratory tract which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claims 18 or a pharmaceutically acceptable salt thereof.

26. (New) A method of treatment according to claim 25 in which the disease is allergic rhinitis.

27. (New) A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 19 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

28. (New) A method of treatment of diseases of the upper respiratory tract which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claims 19 or a pharmaceutically acceptable salt thereof.

29. (New) A method of treatment according to claim 28 in which the disease is allergic rhinitis.